Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study
A. C. Testa(Università Cattolica del Sacro Cuore), D. Timmerman(Rega Institute for Medical Research), E. Epstein(Karolinska Institutet), D. Fischerová(Charles University), T. Bourne(Luigi Sacco Hospital), L. Savelli(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), L. Valentin(Malmö University), Ignace Vergote(KU Leuven), Robert Fruscio(Azienda Ospedaliera San Gerardo), Laure Wynants(Maastricht University), D. Franchi(European Institute of Oncology), Artur Czekierdowski(Medical University of Lublin), J. Kaijser(KU Leuven), Ben Van Calster(University Medical Center Utrecht), F. Leone(University of Milan), C. Van Holsbeke(Ziekenhuis Oost-Limburg), S. Guerriero(University of Cagliari)
Cited by 122
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
|Journal of Clinical Oncology|2000|840
A calibration hierarchy for risk models was defined: from utopia to empirical data
|Journal of Clinical Epidemiology|2016|834